Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P05231 (interleukin-6)
 23,907 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Smoking is one of the most important risk factors of atherosclerosis and ischaemic heart disease. Endothelial dysfunction is a pathological result of smoking. The aim of the study was to examine the influence of cigarette smoking on biochemical parameters of endothelial function in persons with angiographically confirmed coronary arteries atherosclerosis. The study group included 117 men: 55 patients (mean age 58.8 +/- 10.4) with ischaemic heart disease and 62 healthy subjects (mean age 47.1 +/- 9.3) of control group. In all patients blood lipid concentrations, biochemical parameters of endothelial function (nitric oxide, endothelin-1, sICAM, selectin-E), and inflammation parameters (interleukin-1 beta, interleukin-6) were measured. In a group of smoking patients both: with atherosclerosis and in control subjects nitric oxide (NO) concentrations in serum were decreased in comparison to nonsmokers. In patients with diagnosed coronary arteries atherosclerosis interleukin-6 and sICAM concentrations were increased in comparison to non-smokers. It is concluded that cigarette smoking activates or maintains inflammatory reaction in vessels with atherosclerotic changes.
Pol Arch Med Wewn 2004 Jan
PMID:[Effect of tobacco smoking on endothelial function in patients with coronary arteriosclerosis]. 1508 18

Heart failure (HF) is a complex clinical syndrome due to ischaemic heart disease, idiopathic cardiomyopathy, hypertension, valve heart disease and others. It is not clear if the etiology of HF influences decreased in this syndrome exercise tolerance. Controversial is also dependence of cytokine levels on etiology of HF. The aim of the study was to compare exercise capacity and cytokines levels in pts with ischaemic and dilated cardiomyopathy. We analyzed circulating levels of TNF-alpha and its soluble receptors sTNF-RI and sTNF-RII, and interleukin-1beta (IL-1beta), and interleukin-6 (IL-6) in 41 pts with CHF, functional class NYHA I-IV, mean EF--25.2 +/- 7.1%. For determination of cytokines level (using R & D System tests) venous blood was withdrawn after 30 minutes of supine rest. All underwent echocardiography and cardiopulmonary exercise stress testing. Dilated cardiomyopathy (DCM) was diagnosed in 21 pts, ischaemic (ICM) in 20 pts. Pts with DCM were younger then with ICM (48 +/- 6.6 vs 56 +/- 6.6 yrs; p = 0.001). There were no significant differences between groups concerning BMI and EF. There were no significant differences in the level of TNF-alpha and sTNF-RI between groups. There was a trend of increased sTNF-RII in pts with ICM (3179.7 +/- 832.7 vs 2699 +/- 680.1 pg/ml; p = 0,07), IL-1beta (2.55 +/- 2.41 vs 1.49 +/- 1.68 pg/ml; p = 0.087) and IL-6 (6.25 +/- 2.21 vs 4.98 +/- 3.64 pg/ml; p = 0.065), and significant increased ESR (11.2 +/- 9.5 vs 5.5 +/- 4.7 mm/h; p = 0.04). Peak VO2 was reduced in pts with ICM group as compared to those with DCM (14.1 +/- 3.7 vs 18.1 +/- 4.8 ml/kg/min; p = 0.0069). In chronic heart failure circulating levels of cytokines tended to be higher in pts with ischaemic origin of the syndrome. The exercise capacity is lower in ischaemic cardiomyopathy.
Pol Arch Med Wewn 2004 Jun
PMID:[Cardiopulmonary exercise testing and cytokines in chronic heart failure. Comparison of patients with ischaemic and with dilated cardiomyopathy]. 1550 92

Proinflammatory cytokines, such as tumor necrosis factor alpha (TNF-alpha), interleukin-1 (IL-1) and interleukin-6 (IL-6), act as mediators of post-injury inflammation and increase pain sensitivity. Pentoxifylline (PTX) has the property of inhibiting TNF-alpha, IL-1, and IL-6 production. Previous studies revealed that the pre-injury or preoperative administration of PTX inhibited consequent hyperalgesia or postoperative pain. The aim of the study was to determine, if postoperative PTX administration affects postoperative pain. A group of 40 patients undergoing laparotomic cholecystectomy received postoperatively PTX at 10 mg/kg or placebo directly after the termination of general anesthesia. There were no differences in postoperative pain, analgesic drug requirement or TNF-alpha and IL-6 serum levels between the groups.
Pol J Pharmacol
PMID:Pentoxifylline does not affect nociception if administered postoperatively. 1559 51

We investigated serum levels of interleukin-6 (IL-6) and tumor necrosis factor alpha (TNFalpha) in 25 patients with juvenile idiopathic arthritis (JIA) during both: active and inactive phases of the disease. The polyarticular JIA patients had the highest IL-6 level during both active and inactive periods, TNFalpha level was the highest in the systemic JIA, active and inactive periods. IL-6 and TNFalpha levels were significantly lower than those of controls (p<0.0003) in oligoarticular JIA. IL-6 correlated significantly with C-related protein (CRP) in active period (p<0.001) and inactive period (p<0.05) in oligoarticular JIA patients, such correlation was not found for TNFalpha. In conclusion, IL-6 and CRP may play an important role in JIA and may be used as a marker of disease activity.
Pol Merkur Lekarski 2004 Sep
PMID:[Cytokine levels in serum of patients with juvenile idiopathic arthritis depending on subtype and disease activity]. 1562 47

Serum interleukin-6 concentrations in patients with alcoholic liver disease Pathogenesis of alcoholic liver disease (ALD) is not well defined, but immune mediated hepatic injury is thought to be important. The main aim of this study was estimation of serum concentrations of IL-6 in patients with chronic alcoholic liver disease and determination of correlations between IL-6 serum concentration and occurrence of clinical manifestations, biochemical parameters and a stage of ALD. 85 patients with the diagnosis of chronic ALD and 35 healthy subjects (mached for age and sex) were enrolled into the study. Serum concentration of IL-6 was measured with ELISA. Serum IL-6 concentrations were markedly elevated in the all analyzed groups of patients with ALD when compared with healthy controls. When compared in groups, patients with alcoholic cirrhosis and chronic alcoholic hepatitis had the highest and patients with fatty liver had the lowest serum IL-6 concentrations. In addition, IL-6 concentrations were higher in patients with hepatic encephalopathy than in those without liver failure. Furthermore, we found statistically significant correlation between serum IL-6 and albumin concentrations. High IL-6 concentrations were associated with high mortality in patients with ALD. These findings suggest that IL-6 is an important immunological factor associated with alcoholic liver disease.
Pol Merkur Lekarski 2004 Sep
PMID:[Serum interleukin-6 concentrations in patients with alcoholic liver disease]. 1562 53

Tumor necrosis factor (TNF) and interleukin-6 (IL-6) are pleiotropic cytokines produced by immune and nonimmune cells. Inappropriate expression and production of TNF and IL-6 is thought to be involved in the pathogenesis of numerous diseases, including atherosclerosis which leads to coronary heart disease, osteoporosis and Alzheimer's disease. Conversely, these disorders belong to the late complications of menopause and hormone replacement therapy (HRT) may successfully improve them. Several studies have shown that postmenopausal women show an enhanced expression of TNF and IL-6. On contrary, the use of hormone replacement therapy by postmenopausal women has been shown to down regulate this overexpression. Therefore, the mechanisms underlying the protective effects of HRT can also be attributed to its immunomodulating properties which seem to restore cytokine homeostasis in postmenopausal women.
Pol Merkur Lekarski 2005 Jun
PMID:[Role of tumor necrosis factor (TNF) and interleukin-6 (IL-6) in the pathogenesis of late complications of menopause. Effects of hormone replacement therapy on TNF and IL-6 expression]. 1612 93

Rheumatoid arthritis (RA) is a chronic inflammatory disease in which cytokines play an important role. The therapy of RA is associated with application of the drugs modulating the immune response via inhibiting the cytokine production. The common drugs used in RA therapy are methotrexate and prednisone. Recent investigations showed the importance of genetically determined differences in cytokine production in RA activity and therapy. The aim of the present study was to examine the influence of - 174 interleukin-6 (IL-6) promoter polymorphism on the efficacy of treatment of RA patients with methotrexate and prednisone. Polymerase chain reaction amplification was used for analysis of the polymorphism at IL-6 gene. Seventy patients with RA diagnosed according to the criteria of the American College of Rheumatology were investigated. The patients were divided into two subgroups. The first subgroup included patients who have obtained remission for at least 6 months after therapy with methotrexate and glucocorticosteroids. The second subgroup included patients with active disease despite at least 6 months of therapy with methotrexate and glucocorticosteroids. It has been shown that the incidence of remission after therapy with methotrexate and glucocorticosteroids was significantly lower in patients with GG genotype as compared with GC and CC genotypes p< 0.05. We suggest that -174 IL-6 promoter polymorphism may be a genetic risk factor determining the effectiveness of RA treatement with methotrexate and glucocorticosteroids.
Pol Arch Med Wewn 2005 Sep
PMID:[The influence of IL-6 polymorphism on efficacy of treatment of rheumatoid arthritis patients with methotrexate and prednisone]. 1670 57

Inflammatory processes have important roles in the etiology of atherosclerosis. Several studies have shown that elevated plasma levels of C-reactive protein (CRP), tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), adhesions molecules, monocyte chemoattractant protein-1 (MCP-1) are associated with the risk of coronary heart disease. Fibrates, agonists of peroxisome proliferator-activated receptors alpha (PPARalpha), act to modulate the expression of key genes of lipid transport and metabolism in the liver and adipose tissue. Besides the hipolipemic effects they exert pleiotropic, anti-inflammatory properties downregulating expression of genes encoding acute phase proteins and inflammatory cytokines. In this article, we briefly review the clinical trial data on the effects of fibrates on the inflammatory markers.
Pol Merkur Lekarski 2007 Jan
PMID:[Fibrates and markers of inflammation]. 1747 93

Pro-inflammatory cytokines may accelerate development and progression of atherosclerotic process. Interleukin-6 (IL- 6) in such state has essential role. It is caused by its direct and indirect effect on other cytokines, acute phase proteins and endothelial cells. In our work we presented the role of IL-6 in development and progression of atherosclerosis. The influence of traditional risk factors on its secretion was also described. We presented also study in which IL-6 was use to risk assessment of cardiovascular disease both in primary and secondary prevention.
Pol Merkur Lekarski 2007 Apr
PMID:[The role of interleukin-6 in development and progression of atherosclerosis]. 1768 29

Interleukin-6 (IL-6) is proinflammatory cytokine that produces multifunctional effects. It is also involved in the regulation of immune reactions, hematopoiesis and inflammatory state. Interleukin-6 has been shown to be associated with tumor progression including inhibition of cancer cells apoptosis and stimulation of angiogenesis. Anti-IL-6 therapy is a new strategy in the inflammatory autoimmune diseases and cancer. Clinical studies have shown elevated serum IL-6 concentrations in patients with endometrial cancer, non-small cell lung carcinoma, colorectal cancer, renal cell carcinoma, breast and ovarian cancer. Serum IL-6 levels correlate with tumor stage, and survival of patients. In this article we have focused on a role of IL-6 as a prognostic factor in several malignancies such as colorectal cancer, breast cancer, gastric cancer and pancreatic cancer.
Pol Arch Med Wewn
PMID:[Clinical significance of interleukin-6 (IL-6) as a prognostic factor of cancer disease]. 1803 Aug 75


<< Previous 1 2 3 4 5 Next >>